Waverton Investment Management Ltd reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 5.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 156,209 shares of the biopharmaceutical company’s stock after selling 8,292 shares during the period. Pfizer comprises 0.3% of Waverton Investment Management Ltd’s investment portfolio, making the stock its 29th largest holding. Waverton Investment Management Ltd’s holdings in Pfizer were worth $5,667,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in PFE. Fort L.P. bought a new stake in Pfizer in the second quarter valued at approximately $121,000. Braun Bostich & Associates Inc. bought a new stake in Pfizer in the first quarter valued at approximately $139,000. Smart Portfolios LLC boosted its holdings in Pfizer by 43.9% in the second quarter. Smart Portfolios LLC now owns 3,935 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 1,200 shares during the last quarter. Goodwin Daniel L bought a new stake in Pfizer in the second quarter valued at approximately $171,000. Finally, Point72 Hong Kong Ltd boosted its holdings in Pfizer by 7,195.5% in the second quarter. Point72 Hong Kong Ltd now owns 4,815 shares of the biopharmaceutical company’s stock valued at $175,000 after acquiring an additional 4,749 shares during the last quarter. Institutional investors own 69.42% of the company’s stock.
Several equities analysts have issued reports on PFE shares. Barclays set a $40.00 price target on Pfizer and gave the company a “neutral” rating in a research note on Wednesday, August 29th. Atlantic Securities reissued a “buy” rating and issued a $54.00 price target on shares of Pfizer in a research note on Tuesday, November 27th. Deutsche Bank set a $45.00 price target on Pfizer and gave the company a “buy” rating in a research note on Tuesday, August 21st. Cantor Fitzgerald set a $53.00 price target on Pfizer and gave the company a “buy” rating in a research note on Thursday, November 8th. Finally, Morgan Stanley set a $45.00 price target on Pfizer and gave the company a “buy” rating in a research note on Thursday, September 13th. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating and nine have assigned a buy rating to the stock. Pfizer presently has a consensus rating of “Hold” and a consensus price target of $43.27.
In other news, major shareholder Pfizer Inc bought 55,556 shares of the stock in a transaction dated Monday, October 15th. The shares were bought at an average cost of $18.00 per share, with a total value of $1,000,008.00. Following the completion of the transaction, the insider now directly owns 21,976,484 shares of the company’s stock, valued at $395,576,712. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is owned by corporate insiders.
Shares of NYSE:PFE opened at $43.92 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.47. Pfizer Inc. has a twelve month low of $33.20 and a twelve month high of $46.47. The company has a market cap of $267.76 billion, a PE ratio of 16.57, a PEG ratio of 2.24 and a beta of 0.88.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.03. Pfizer had a return on equity of 25.26% and a net margin of 44.63%. The company had revenue of $13.30 billion for the quarter, compared to analyst estimates of $13.53 billion. During the same period in the prior year, the firm earned $0.67 earnings per share. Pfizer’s revenue for the quarter was up 1.0% on a year-over-year basis. Equities analysts predict that Pfizer Inc. will post 3 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Monday, December 3rd. Stockholders of record on Friday, November 9th were given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.10%. The ex-dividend date of this dividend was Thursday, November 8th. Pfizer’s payout ratio is 51.32%.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
See Also: Swap
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.